369 related articles for article (PubMed ID: 26327679)
1. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis.
Sedel F; Bernard D; Mock DM; Tourbah A
Neuropharmacology; 2016 Nov; 110(Pt B):644-653. PubMed ID: 26327679
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
Peyro Saint Paul L; Debruyne D; Bernard D; Mock DM; Defer GL
Expert Opin Drug Metab Toxicol; 2016; 12(3):327-44. PubMed ID: 26699811
[TBL] [Abstract][Full Text] [Related]
3. Intersections of pathways involving biotin and iron relative to therapeutic mechanisms for progressive multiple sclerosis.
Heidker RM; Emerson MR; LeVine SM
Discov Med; 2016 Dec; 22(123):381-387. PubMed ID: 28147220
[TBL] [Abstract][Full Text] [Related]
4. High doses of biotin in chronic progressive multiple sclerosis: a pilot study.
Sedel F; Papeix C; Bellanger A; Touitou V; Lebrun-Frenay C; Galanaud D; Gout O; Lyon-Caen O; Tourbah A
Mult Scler Relat Disord; 2015 Mar; 4(2):159-69. PubMed ID: 25787192
[TBL] [Abstract][Full Text] [Related]
5. Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection?
Dubessy AL; Zujovic V; Papeix C; Stankoff B
Rev Neurol (Paris); 2014 Dec; 170(12):770-8. PubMed ID: 25459127
[TBL] [Abstract][Full Text] [Related]
6. Stem cell therapy for demyelinating disorders.
Pazour J; Mokrý J
Acta Medica (Hradec Kralove); 2006; 49(2):79-85. PubMed ID: 16956113
[TBL] [Abstract][Full Text] [Related]
7. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis.
Trapp BD; Stys PK
Lancet Neurol; 2009 Mar; 8(3):280-91. PubMed ID: 19233038
[TBL] [Abstract][Full Text] [Related]
8. Remyelinating strategies in multiple sclerosis.
Luessi F; Kuhlmann T; Zipp F
Expert Rev Neurother; 2014 Nov; 14(11):1315-34. PubMed ID: 25331418
[TBL] [Abstract][Full Text] [Related]
9. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA
Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532
[TBL] [Abstract][Full Text] [Related]
10. Pathology of multiple sclerosis and related inflammatory demyelinating diseases.
Kutzelnigg A; Lassmann H
Handb Clin Neurol; 2014; 122():15-58. PubMed ID: 24507512
[TBL] [Abstract][Full Text] [Related]
11. Demyelination versus remyelination in progressive multiple sclerosis.
Bramow S; Frischer JM; Lassmann H; Koch-Henriksen N; Lucchinetti CF; Sørensen PS; Laursen H
Brain; 2010 Oct; 133(10):2983-98. PubMed ID: 20855416
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of pathogenesis in multiple sclerosis: implications for promotion of remyelination.
Paz Soldan MM; Rodriguez M
J Infect Dis; 2002 Dec; 186 Suppl 2():S248-53. PubMed ID: 12424705
[TBL] [Abstract][Full Text] [Related]
13. Gender differences in the histopathology of MS?
Kuhlmann T; Goldschmidt T; Antel J; Wegner C; König F; Metz I; Brück W
J Neurol Sci; 2009 Nov; 286(1-2):86-91. PubMed ID: 19674757
[TBL] [Abstract][Full Text] [Related]
14. Influence of Peripheral inflammation on the progression of multiple sclerosis: evidence from the clinic and experimental animal models.
Murta V; Ferrari CC
Mol Cell Neurosci; 2013 Mar; 53():6-13. PubMed ID: 22771835
[TBL] [Abstract][Full Text] [Related]
15. Tardive Reactivation of Progressive Multiple Sclerosis During Treatment with Biotin.
Demas A; Cochin JP; Hardy C; Vaschalde Y; Bourre B; Labauge P
Neurol Ther; 2020 Jun; 9(1):181-185. PubMed ID: 31858407
[TBL] [Abstract][Full Text] [Related]
16. Is there a Link between Vitamin B and Multiple Sclerosis?
Nemazannikova N; Mikkelsen K; Stojanovska L; Blatch GL; Apostolopoulos V
Med Chem; 2018 Feb; 14(2):170-180. PubMed ID: 28875857
[TBL] [Abstract][Full Text] [Related]
17. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies.
Faissner S; Plemel JR; Gold R; Yong VW
Nat Rev Drug Discov; 2019 Dec; 18(12):905-922. PubMed ID: 31399729
[TBL] [Abstract][Full Text] [Related]
18. Promoting remyelination in multiple sclerosis: current drugs and future prospects.
Kremer D; Küry P; Dutta R
Mult Scler; 2015 Apr; 21(5):541-9. PubMed ID: 25623245
[TBL] [Abstract][Full Text] [Related]
19. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
Karussis D
J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis.
Correale J; Marrodan M; Ysrraelit MC
Biomedicines; 2019 Feb; 7(1):. PubMed ID: 30791637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
